Implantable Cardioverter Defibrillator, Electromechanical Interference, Ventricular Assist Device. An increasing number of patients have a coexisting implantable cardioverter defibrillator (ICD) and left ventricular assist device (LVAD) to treat ventricular arrhythmias and refractory heart failure, respectively. To date, there have been no published reports of negative interactions between these devices that have impacted appropriate ICD or LVAD function. In this case report, we describe a patient with an LVAD-ICD interaction that necessitated replacement of the implantable
Introduction
Implantation of a left ventricular assist device as a bridge to cardiac transplantation or as destination therapy for patients with end stage heart failure is becoming increasingly common. In 2005, approximately 1100 LVADs were implanted in the United States (personal communication with Thoratec, May 2006) . Because recent clinical trials have demonstrated the survival benefit of implantable cardioverter defibrillators in patients with heart failure, many LVAD candidates have an ICD in place prior to LVAD surgery. 1, 2 While the discharge of an ICD has not been found to impair the mechanical function of contemporary LVADs, little has been published about the impact of electromagnetic interference from LVADs on ICD function. This case report describes a patient with an interaction between his ICD and HeartMate II LVAD that resulted in an inability to interrogate and program the ICD, ultimately requiring replacement of the ICD. 
Discussion
In the 20 years of LVAD use, this case report represents the first description of an adverse interaction between an LVAD and an ICD requiring replacement of the ICD. In this patient, an adverse interaction with the HeartMate II LVAD prevented telemetry communication between the device programmer and the St. Jude ICD. Intrinsic malfunction of the ICD or its programmer is very unlikely, since both devices functioned normally in the absence of the LVAD. Other sources of electromagnetic interference were considered, but the ICD demonstrated normal interrogation and programming in the same environments both before the LVAD implant and after the St. Jude ICD was removed. Potential causes for the problem include electromagnetic frequencies produced during LVAD operation that are similar to the telemetry frequencies used during ICD interrogation, and programming. Another possibility is that the current shielding available in the ICD is insufficient to prevent electromagnetic interference from the LVAD that is placed in proximity to the ICD.
At the University of Michigan Health System, with over 200 LVAD implants to date, this is the first occurrence of an ICD-LVAD interaction. Of the 80 patients implanted with an LVAD device (53% HeartMate I, 35% HeartMate II, 12% other) at our institution since May 2003, 53 (66%) had a preexisting ICD in place at the time of LVAD surgery. Manufacturer data was available on 45 of the 53 ICDs, and 53% (n = 24) were Medtronic, 40% (n = 18) were Boston Scientific (St. Paul, MN), 4.4% (n = 2) were Biotronik (Lake Oswego, OR), and 2.2% (n = 1) were St. Jude.
The St. Jude Corporation acknowledged previous unpublished instances of similar problems with ICD interrogation and reprogramming in patients after HeartMate II implantation (personal communication with St. Jude Corporation, May 2006). According to the company, the malfunction is caused by electromagnetic interference from the HeartMate II LVAD, impairing telemetry communication between the ICD and the ICD programmer. They also reported that while enabled ICDs function normally in the presence of the HeartMate II, the defibrillator may not be able to be interrogated or programmed while the LVAD functioned at the prescribed speeds. St. Jude also reports that the telemetry frequencies for their implantable pacemakers are similar to that of their ICDs.
Other options suggested by St. Jude Medical were to either reduce the HeartMate II pump speed to 1300 rpm or to increase the pump speed to 11,200-12,000 rpm. However, large changes in HeartMate II pump speeds, even if only transient, could be detrimental to the patient. A reduction in LVAD pump speed to 1300 rpm for the few minutes required to complete an interrogation could lead to hemodynamic compromise and even syncope in patients with severe intrinsic left ventricular dysfunction. Similarly, elevated rotary speeds could quickly reduce left ventricular preload, resulting in poor device flows and clinical decompensation. The Thoratec Corporation does not recommend pump speeds over 10,000 rpm with the HeartMate II.
The Thoratec Corporation stated that they were aware of isolated instances of ICD malfunction in HeartMate II recipients and that these problems appeared specific to ICDs manufactured by the St. Jude Corporation (personal communication with Thoratec Corporation, May 2006). Due to the limited data available, it is unclear if ICDs from other manufacturers could exhibit a similar interaction with the HeartMate II. To date, there have been no reported adverse ICD-LVAD interactions with either the Medtronic or Boston Scientific ICDs. Likewise, it is unknown whether this device interaction is limited to the axial flow LVADs, such as the HeartMate II, or if it can also occur with pulsatile flow LVADs.
While an ICD is not routinely implanted in all patients prior to LVAD surgery, reports describing the deleterious hemodynamic and clinical effects of ventricular arrhythmias in these patients support their use. 3, 4 With the increased use of mechanical circulatory support, more ICD-LVAD interactions may begin to appear. While St. Jude reports that their new generation of devices (including the Atlas ICDs) operate at a higher (4 Hz) frequency, allowing for successful telemetry communication between the programmer and the device during HeartMate II support, many LVAD candidates may still have preexisting older St. Jude devices in place. In patients undergoing LVAD evaluation, clinicians should consider the potential for similar interactions between an ICD or pacemaker and an LVAD, and take appropriate steps to ensure that the device can be interrogated and programmed normally after LVAD insertion.
